EUVIMEDEUVIMED entdecken
Crossref

31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort

Ani Pazhava iD, Yong-Hun Kim, Frank Z Jing iD, Mark R Pittelkow

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Ani Pazhava und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Gene Expression Profiling. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Smith Gibson Fellowship, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous melanoma (CM) is a significant health concern because of its high metastatic potential. Gene Expression Profile (GEP) testing, particularly the 31‐GEP test (DecisionDx‐Melanoma), has been increasingly used for risk stratification in CM patients. This study aimed to evaluate the clinical utility and performance of the 31‐GEP test in a real‐world setting.

Methods

Patients with CM who underwent 31‐GEP testing from August 2014 to August 2022 at our institution were identified through searches of electronic health records. The study analyzed the influence of 31‐GEP testing on clinical decision‐making related to sentinel lymph node biopsy (SLNB), medical oncology referral, and postdiagnosis surveillance. Kaplan–Meier curves and Cox proportional hazard models were used to elucidate the test's performance, focusing on relapse‐free survival (RFS) and melanoma‐specific survival (MSS).

Results

The study included 65 CM patients. Dermatologists ordered more than 80% of 31‐GEP tests. In 81.5% of cases, 31‐GEP results did not alter standard clinical management. SLNB decisions were unaffected in 92% of patients with pre‐SLNB 31‐GEP results. Among patients with stage I‐IIA melanoma, 25% of those with high‐risk 31‐GEP results were referred to medical oncology. Contrary to expectations, the rate of nodal metastasis was higher in low‐risk than in high‐risk 31‐GEP cases. Survival analysis showed overlapping RFS and MSS curves between different 31‐GEP classes, suggesting limited prognostic value.

Conclusions

The 31‐GEP test has a limited impact on clinical management decisions and shows limited prognostic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsGene Expression ProfilingHumansFemaleMaleMiddle AgedAgedSentinel Lymph Node BiopsyClinical Decision-MakingAdultRisk AssessmentRetrospective StudiesNeoplasm StagingAged, 80 and overReferral and ConsultationKaplan-Meier EstimateDisease-Free Survival

Stichwörter der Autor:innen

31‐GEPDecisionDxcutaneous metastatic diseasegene expression profilemelanomaskin cancer

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
  • Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA.

ORCID-Profile: Ani Pazhava, Frank Z Jing

Förderung

  • Smith Gibson Fellowship
  • Mayo Clinic

Zitieren

APA

Pazhava, A., Kim, Y. H., Jing, F. Z., & Pittelkow, M. R. (2025). 31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort. International Journal of Dermatology. https://doi.org/10.1111/ijd.17440

Vancouver

Pazhava A, Kim YH, Jing FZ, Pittelkow MR. 31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort. International Journal of Dermatology. 2025. doi:10.1111/ijd.17440

BibTeX
@article{Pazhava2025,
  author = {Pazhava, Ani and Kim, Yong-Hun and Jing, Frank Z and Pittelkow, Mark R},
  title = {31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17440}
}
Kostenlos starten →